Compare Halliburton Company (HAL) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs McKesson Corporation — how do they compare? Halliburton Company trades at $32.6 (market cap $27.14B), while McKesson Corporation trades at $933.93 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 4× Halliburton Company's market cap, and Halliburton Company pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and McKesson Corporation for 74 Days on average.
| HAL | MCK | |
|---|---|---|
Market Cap | $27.14B | $108.46B |
Volume | 11,258,156 | 712,607 |
Sector | Energy | Health |
52-Week High | $42.98 | $995.69 |
52-Week Low | $21.82 | $725.17 |
Typical Hold Time | 89 Days | 74 Days |
Enterprise Value | $33.29B | $115.00B |
Dividend Yield | 2.09% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $31.75, down 2.96% on the day, reflecting near-term bearish technical signals despite strong analyst support. The stock shows solid fundamentals with a P/E of 17.05 and consistent earnings beats in recent quarters. Recent news highlights expansion in Venezuela and a new contract in Cyprus, positioning the company for growth in international energy markets. Cash flow trends indicate variability, with 2025 net cash flow negative but projected to turn positive in 2026.
The outlook for HAL is cautiously optimistic, driven by international contracts and analyst consensus pointing to significant upside with a $43.11 price target. Key risks include oil price volatility and execution challenges in new markets. Investment opportunity lies in the company's strategic expansions and robust profitability metrics, though investors should weigh macroeconomic factors affecting the energy sector.
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
